33,875 Shares in Oruka Therapeutics, Inc. (NASDAQ:ORKA) Bought by 683 Capital Management LLC

683 Capital Management LLC acquired a new stake in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 33,875 shares of the company's stock, valued at approximately $657,000. 683 Capital Management LLC owned 0.10% of Oruka Therapeutics at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of ORKA. Geode Capital Management LLC bought a new position in Oruka Therapeutics in the 3rd quarter worth approximately $343,000. Franklin Resources Inc. acquired a new position in shares of Oruka Therapeutics during the third quarter valued at $17,661,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Oruka Therapeutics during the fourth quarter valued at about $144,000. AlphaCentric Advisors LLC acquired a new stake in Oruka Therapeutics in the fourth quarter worth about $119,000. Finally, Charles Schwab Investment Management Inc. bought a new position in Oruka Therapeutics in the 4th quarter valued at about $303,000. Institutional investors own 56.44% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on ORKA. HC Wainwright restated a "buy" rating and issued a $45.00 price objective on shares of Oruka Therapeutics in a report on Friday, February 7th. Wolfe Research started coverage on shares of Oruka Therapeutics in a research note on Tuesday, February 4th. They set an "outperform" rating and a $20.00 price target on the stock. Finally, Wedbush restated an "outperform" rating and issued a $40.00 price objective on shares of Oruka Therapeutics in a research note on Friday, March 7th. Seven analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $39.86.

Oruka Therapeutics Price Performance

Shares of Oruka Therapeutics stock traded down $0.73 during trading on Monday, hitting $9.98. 110,086 shares of the company's stock traded hands, compared to its average volume of 233,681. Oruka Therapeutics, Inc. has a twelve month low of $5.49 and a twelve month high of $31.13. The company has a market cap of $373.66 million, a PE ratio of -1.59 and a beta of 0.25. The firm's fifty day moving average price is $9.99 and its 200 day moving average price is $16.07.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last posted its quarterly earnings data on Thursday, March 6th. The company reported ($0.49) earnings per share for the quarter, topping the consensus estimate of ($0.68) by $0.19. As a group, equities research analysts anticipate that Oruka Therapeutics, Inc. will post -3.41 earnings per share for the current year.

Insiders Place Their Bets

In related news, major shareholder Venrock Healthcare Capital Par purchased 88,794 shares of Oruka Therapeutics stock in a transaction dated Friday, February 14th. The shares were acquired at an average cost of $11.44 per share, for a total transaction of $1,015,803.36. Following the transaction, the insider now directly owns 4,148,428 shares of the company's stock, valued at approximately $47,458,016.32. This trade represents a 2.19 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. In the last quarter, insiders have bought 98,339 shares of company stock valued at $1,128,456. 22.67% of the stock is currently owned by corporate insiders.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.